ShineOn’s exclusive technology addresses protein precipitation caused by unexpected folding in a structure composed of multi-specific antibodies, offering a great flexibility in multi-specific antibody design for enhanced targeting efficacy. This advancement reduces the effective dosage required compared to mono-specific and bispecific antibodies, thereby improving drug safety.
Two pipeline antibody products have been developed referring to SOA101 and SOA201.
